{
  "pmcid": "10556815",
  "sha256": "c4fed12907dee424a28cf3afb4429af9193ee51c6c6dd0589163ab8d1c497d8f",
  "timestamp_utc": "2025-11-09T23:07:34.062552+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.4730383480826,
    "reading_ease": 13.661022615535927,
    "word_count": 226
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Diazoxide Cardioprotection in Mouse Models of Global Ischemia"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Sample size calculations were based on detecting a 5% ± 4% difference with 80% power."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Myocytes were exposed to Tyrode's solution, hyperkalemic cardioplegia (CPG) ± diazoxide, ± VU591 (Kir1.1 inhibitor), and Tyrode's solution again."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to elucidate its mechanism of action to develop targeted therapies for cardiac surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was measured over a 20-minute period for myocytes and a 90-minute ischemia with 30-minute reperfusion for hearts."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Investigators were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Myocyte contractility was reduced by CPG but preserved by diazoxide. VU591 negated diazoxide's effect in myocytes. In hearts, diazoxide improved left ventricular function post-ischemia in all mouse types."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}